FATE
Price
$1.10
Change
+$0.04 (+3.77%)
Updated
Nov 26 closing price
Capitalization
126.89M
95 days until earnings call
Intraday BUY SELL Signals
IMTX
Price
$10.61
Change
-$0.36 (-3.28%)
Updated
Nov 26 closing price
Capitalization
1.29B
118 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FATE vs IMTX

Header iconFATE vs IMTX Comparison
Open Charts FATE vs IMTXBanner chart's image
Fate Therapeutics
Price$1.10
Change+$0.04 (+3.77%)
Volume$754.84K
Capitalization126.89M
Immatics
Price$10.61
Change-$0.36 (-3.28%)
Volume$641.92K
Capitalization1.29B
FATE vs IMTX Comparison Chart in %
FATE
Daily Signal:
Gain/Loss:
IMTX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
FATE vs. IMTX commentary
Nov 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a StrongBuy and IMTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 28, 2025
Stock price -- (FATE: $1.10 vs. IMTX: $10.60)
Brand notoriety: FATE and IMTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 31% vs. IMTX: 75%
Market capitalization -- FATE: $126.89M vs. IMTX: $1.29B
FATE [@Biotechnology] is valued at $126.89M. IMTX’s [@Biotechnology] market capitalization is $1.29B. The market cap for tickers in the [@Biotechnology] industry ranges from $109.65B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileIMTX’s FA Score has 0 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • IMTX’s FA Score: 0 green, 5 red.
According to our system of comparison, IMTX is a better buy in the long-term than FATE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 7 TA indicator(s) are bullish while IMTX’s TA Score has 3 bullish TA indicator(s).

  • FATE’s TA Score: 7 bullish, 4 bearish.
  • IMTX’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, FATE is a better buy in the short-term than IMTX.

Price Growth

FATE (@Biotechnology) experienced а +4.76% price change this week, while IMTX (@Biotechnology) price change was +2.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -1.24%, and the average quarterly price growth was +71.95%.

Reported Earning Dates

FATE is expected to report earnings on Mar 02, 2026.

IMTX is expected to report earnings on Mar 25, 2026.

Industries' Descriptions

@Biotechnology (+4.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMTX($1.29B) has a higher market cap than FATE($127M). IMTX YTD gains are higher at: 49.086 vs. FATE (-33.333). IMTX has higher annual earnings (EBITDA): -58.05M vs. FATE (-161.6M). IMTX has more cash in the bank: 478M vs. FATE (223M). IMTX has less debt than FATE: IMTX (17.1M) vs FATE (81.3M). IMTX has higher revenues than FATE: IMTX (130M) vs FATE (8.47M).
FATEIMTXFATE / IMTX
Capitalization127M1.29B10%
EBITDA-161.6M-58.05M278%
Gain YTD-33.33349.086-68%
P/E RatioN/A27.61-
Revenue8.47M130M7%
Total Cash223M478M47%
Total Debt81.3M17.1M475%
FUNDAMENTALS RATINGS
FATE vs IMTX: Fundamental Ratings
FATE
IMTX
OUTLOOK RATING
1..100
49
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
74
Overvalued
PROFIT vs RISK RATING
1..100
10097
SMR RATING
1..100
9591
PRICE GROWTH RATING
1..100
8836
P/E GROWTH RATING
1..100
10053
SEASONALITY SCORE
1..100
5036

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (13) in the Biotechnology industry is somewhat better than the same rating for IMTX (74) in the null industry. This means that FATE’s stock grew somewhat faster than IMTX’s over the last 12 months.

IMTX's Profit vs Risk Rating (97) in the null industry is in the same range as FATE (100) in the Biotechnology industry. This means that IMTX’s stock grew similarly to FATE’s over the last 12 months.

IMTX's SMR Rating (91) in the null industry is in the same range as FATE (95) in the Biotechnology industry. This means that IMTX’s stock grew similarly to FATE’s over the last 12 months.

IMTX's Price Growth Rating (36) in the null industry is somewhat better than the same rating for FATE (88) in the Biotechnology industry. This means that IMTX’s stock grew somewhat faster than FATE’s over the last 12 months.

IMTX's P/E Growth Rating (53) in the null industry is somewhat better than the same rating for FATE (100) in the Biotechnology industry. This means that IMTX’s stock grew somewhat faster than FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FATEIMTX
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 14 days ago
90%
Bearish Trend 18 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
FATE
Daily Signal:
Gain/Loss:
IMTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JHUKX40.630.41
+1.02%
JPMorgan Emerging Markets Equity R4
KTCAX47.19N/A
N/A
DWS Science and Technology A
GCEDX11.10N/A
N/A
Goldman Sachs Clean Energy Income Ins
PCVAX11.91N/A
N/A
Virtus NFJ Small-Cap Value A
BAFSX45.91N/A
N/A
Brown Advisory Small-Cap Growth Inst

IMTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMTX has been loosely correlated with IDYA. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if IMTX jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMTX
1D Price
Change %
IMTX100%
-3.37%
IDYA - IMTX
55%
Loosely correlated
+1.13%
VYGR - IMTX
51%
Loosely correlated
+1.51%
SYRE - IMTX
51%
Loosely correlated
+1.88%
RGNX - IMTX
51%
Loosely correlated
-1.52%
CGON - IMTX
51%
Loosely correlated
-1.36%
More